The addition of temozolomide does not change the pattern of progression of glioblastoma multiforme post-radiotherapy

Journal of Medical Imaging and Radiation Oncology

Volumn 56, Issue 5, 2012, Pages 567-573

  Gunjur, Ashray ^a   Bressel, Mathias ^b   Ryan, Gail ^a,b  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b PETER MACCALLUM CANCER CENTRE   (Australia)

Author keywords

glioblastoma multiforme; in field progression; out of field progression; radiotherapy; temozolomide

Indexed keywords

TEMOZOLOMIDE;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; COMPUTER ASSISTED RADIOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; DISEASE COURSE; FEMALE; GLIOBLASTOMA; HISTOGRAM; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RADIATION DOSE FRACTIONATION; TREATMENT PLANNING;

EID: 84867394109     PISSN: 17549477     EISSN: 17549485     Source Type: Journal    
DOI: 10.1111/j.1754-9485.2012.02414.x     Document Type: Article

References (27)

1. Stupp R, Mason WP, van den, Bent MJ, et al,. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352: 987-996.
2. Walker MD, Alexander E, Hunt WE, et al,. Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial. J Neurosurg 1978; 49: 333-343.
3. Walker MD, Strike TA, Sheline GE,. An analysis of dose-effect relationship in the radiotherapy of malignant gliomas. Int J Radiat Oncol Biol Phys 1979; 5: 1725-1731.
4. Bleehen NM, Stenning SP,. A Medical Research Council trial of two radiotherapy doses in the treatment of grades 3 and 4 astrocytoma. The Medical Research Council Brain Tumour Working Party. Br J Cancer 1991; 64: 769-774.
5. Johnson PC, Hunt SJ, Drayer BP,. Human cerebral gliomas: correlation of postmortem MR imaging and neuropathologic findings. Radiology 1989; 170: 211-217.
6. Watanabe M, Tanaka R, Takeda N,. Magnetic resonance imaging and histopathology of cerebral gliomas. Neuroradiology 1992; 34: 463-469.
7. van den Hauwe L, Parizel PM, Martin JJ, Cras P, Deyn P, Schepper AMA,. Postmortem MRI of the brain with neuropathological correlation. Neuroradiology 1995; 37: 343-349.
8. Burger PC, Dubois PJ, Schold SC Jr, et al,. Computerized tomographic and pathologic studies of the untreated, quiescent, and recurrent glioblastoma multiforme. J Neurosurg 1983; 58: 159-169.
9. Greene GM, Hitchon PW, Schelper RL, Yuh W, Dyste GN,. Diagnostic yield in CT-guided stereotactic biopsy of gliomas. J Neurosurg 1989; 71: 494-497.
10. Liang BC, Thornton AF, Sandler HM, Greenberg HS,. Malignant astrocytomas: focal tumor recurrence after focal external beam radiation therapy. J Neurosurg 1991; 75: 559-563.
11. Hess CF, Schaaf JC, Kortmann RD, Schabet M, Bamberg M,. Malignant glioma: patterns of failure following individually tailored limited volume irradiation. Radiother Oncol 1994; 30: 146-149.
12. Oppitz U, Maessen D, Zunterer H, Richter S, Flentje M,. 3D-recurrence-patterns of glioblastomas after CT-planned postoperative irradiation. Radiother Oncol 1999; 53: 53-57.
13. Aydın H, Sillenberg I, von, Lieven H,. Patterns of failure following CT-Based 3-D irradiation for malignant glioma. Strahlenther Onkol 2001; 177: 424-431.
14. Colman H, Berkey BA, Maor MH, et al,. Phase II Radiation Therapy Oncology Group trial of conventional radiation therapy followed by treatment with recombinant interferon-[beta] for supratentorial glioblastoma: results of RTOG 9710. Int J Radiat Oncol Biol Phys 2006; 66: 818-824.
15. Brandes AA, Tosoni A, Franceschi E, et al,. Recurrence pattern after temozolomide concomitant with and adjuvant to radiotherapy in newly diagnosed patients with glioblastoma: correlation with MGMT promoter methylation status. J Clin Oncol 2009; 27: 1275-1279.
16. Macdonald DR, Cascino TL, Schold SC, Cairncross JG,. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 1990; 8: 1277-1280.
17. Lee SW, Fraass BA, Marsh LH, et al,. Patterns of failure following high-dose 3-D conformal radiotherapy for high-grade astrocytomas: a quantitative dosimetric study. Int J Radiat Oncol Biol Phys 1999; 43: 79-88.
18. Milano MT, Okunieff P, Donatello RS, et al,. Patterns and timing of recurrence after temozolomide-based chemoradiation for glioblastoma. Int J Radiat Oncol Biol Phys 2010; 78: 1147-1155.
19. McDonald MW, Shu HG, Curran WJ Jr, Crocker IR,. Pattern of failure after limited margin radiotherapy and temozolomide for glioblastoma. Int J Radiat Oncol Biol Phys 2011; 79: 130-136.
20. Minniti G, Amelio D, Amichetti M, et al,. Patterns of failure and comparison of different target volume delineations in patients with glioblastoma treated with conformal radiotherapy plus concomitant and adjuvant temozolomide. Radiother Oncol 2010; 97: 377-381.
21. Dobelbower MC, Burnett OL, III, Nordal RA, et al,. Patterns of failure for glioblastoma multiforme following concurrent radiation and temozolomide. J Med Imaging Radiat Oncol 2011; 55: 77-81.
22. Chamberlain MC,. Radiographic patterns of relapse in glioblastoma. J Neurooncol 2011; 101: 319-323.
23. Oh J, Sahgal A, Sanghera P, et al,. Glioblastoma: patterns of recurrence and efficacy of salvage treatments. Can J Neurol Sci 2011; 38: 621-625.
24. Wick W, Stupp R, Beule AC, et al,. A novel tool to analyze MRI recurrence patterns in glioblastoma. Neuro-Oncol 2008; 10: 1019-1024.
25. Chan JL, Lee SW, Fraass BA, et al,. Survival and failure patterns of high-grade gliomas after three-dimensional conformal radiotherapy. J Clin Oncol 2002; 20: 1635-1642.
26. Lee IH, Piert M, Gomez-Hassan D, et al,. Association of 11C-Methionine PET uptake with site of failure after concurrent temozolomide and radiation for primary glioblastoma multiforme. Int J Radiat Oncol Biol Phys 2009; 73: 479-485.
27. Weber DC, Casanova N, Zilli T, et al,. Recurrence pattern after [(18) F] fluoroethyltyrosine-positron emission tomography-guided radiotherapy for high-grade glioma: a prospective study. Radiother Oncol 2009; 93: 586-592.